Design and Validation of a New Assessment Tool for Lichen Planopilaris
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03082560|
Recruitment Status : Active, not recruiting
First Posted : March 17, 2017
Last Update Posted : March 2, 2020
The study's Primary Objective is to design and validate a grading system for objective and accurate assessment of lichen planopilaris.
- To assess change in symptoms such as pain and itch using a Numeric Rating Scale(NRS) scores and quality of life using the Dermatology Life Quality Index (DLQI) scores
- To correlate this grading system with patient skin biopsies evaluating disease activity on a microscopic level
- To correlate this grading system with digital global photography and trichoscopy
|Condition or disease||Intervention/treatment|
|Lichen Planopilaris of Scalp Lichen Plano-Pilaris Lichen Planopilaris Frontal Fibrosing Alopecia||Diagnostic Test: Boston Grade of Activity in Lichen Planopilaris|
|Study Type :||Observational|
|Actual Enrollment :||40 participants|
|Official Title:||Design and Validation of a New Assessment Tool for Lichen Planopilaris, the Boston Grade of Activity in Lichen Planopilaris (Boston GOAL)|
|Actual Study Start Date :||February 10, 2017|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||December 2020|
Healthy adult patients with lichen planopilaris
Diagnostic Test: Boston Grade of Activity in Lichen Planopilaris
A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
- Boston Grade of Activity in Lichen Planopilaris (Boston GOAL) [ Time Frame: 6 months ]Design and validate a grading system for objective and accurate assessment of lichen planopilaris.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03082560
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Maryanne Senna, MD||Massachusetts General Hospital|